INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 414s ago
HOUSE PTR21m ago
SEC 13F21m ago
ROBINHOOD CHAIN21m ago
Public company

IMVTImmunovant, Inc.

CIK 0001764013

EDGAR filingsOpen in network
Disclosed transactions60
Buys / sells0 / 30
Max Insider Score42
Connections12with evidence

IMVT · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
25
GT
Girao TiagoChief Financial Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$188K
6,606 sh
Oct 28, 2026Oct 30, 2026
traded Oct 28, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    Girao TiagoChief Financial Officer · Apr 9, 2026
  • ← Insider ofevidence
    Torti FrankDirector · Apr 9, 2026
  • ← Insider ofevidence
    Fromkin Andrew J.Director · Apr 9, 2026
32
SS
Stout Jay SChief Technology Officer
IMVTImmunovant, Inc.
Open-market sale
SELL
$75K
2,595 sh
Oct 21, 2026
Oct 23, 2026
traded Oct 21, 2026
+2d
SEC FORM 4

Evidence

27
SS
Stout Jay SChief Technology Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$51K
1,596 sh
Oct 7, 2026Oct 9, 2026
traded Oct 7, 2026
+2dSEC FORM 4

Evidence

27
GM
Gloria MelanieChief Operating Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$72K
2,241 sh
Oct 7, 2026Oct 9, 2026
traded Oct 7, 2026
+2dSEC FORM 4

Evidence

27
SS
Stout Jay SChief Technology Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$71K
2,213 sh
Oct 7, 2026Oct 9, 2026
traded Oct 7, 2026
+2dSEC FORM 4

Evidence

24
VC
Van Tuyl ChristopherChief Legal Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$43K
1,327 sh
Oct 7, 2026Oct 9, 2026
traded Oct 7, 2026
+2dSEC FORM 4

Evidence

27
VC
Van Tuyl ChristopherChief Legal Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$103K
2,846 sh
Sep 23, 2026Sep 25, 2026
traded Sep 23, 2026
+2dSEC FORM 4

Evidence

9
PA
Pande AtulDirector
IMVTImmunovant, Inc.
Open-market sale · 10b5-1 plan
SELL$65K
1,500 sh
Aug 28, 2026Aug 28, 2026
traded Aug 28, 2026
+0dSEC FORM 4

Evidence

0
PA
Pande AtulDirector
IMVTImmunovant, Inc.
Option exercise · 10b5-1 plan
M$13K
1,500 sh
Aug 28, 2026Aug 28, 2026
traded Aug 28, 2026
+0dSEC FORM 4

Evidence

0
PA
Pande AtulDirector
IMVTImmunovant, Inc.
Option exercise · 10b5-1 plan
M—
1,500 sh
Aug 28, 2026Aug 28, 2026
traded Aug 28, 2026
+0dSEC FORM 4

Evidence

25
GM
Gloria MelanieChief Operating Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$135K
3,056 sh
Aug 20, 2026Aug 21, 2026
traded Aug 20, 2026
+1dSEC FORM 4

Evidence

23
PA
Pande AtulDirector
IMVTImmunovant, Inc.
Open-market sale · 10b5-1 plan
SELL$57K
1,500 sh
Jun 26, 2026Jun 26, 2026
traded Jun 26, 2026
+0dSEC FORM 4

Evidence

0
PA
Pande AtulDirector
IMVTImmunovant, Inc.
Option exercise · 10b5-1 plan
M—
1,500 sh
Jun 26, 2026Jun 26, 2026
traded Jun 26, 2026
+0dSEC FORM 4

Evidence

13
VC
Van Tuyl ChristopherChief Legal Officer
IMVTImmunovant, Inc.
Option exercise
M—
17.8K sh
Jun 26, 2026Jun 26, 2026
traded Jun 26, 2026
+0dSEC FORM 4

Evidence

42
VC
Van Tuyl ChristopherChief Legal Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$572K
15.0K sh
Jun 26, 2026Jun 26, 2026
traded Jun 26, 2026
+0dSEC FORM 4

Evidence

42
GM
Gloria MelanieChief Operating Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$563K
14.7K sh
Jun 26, 2026Jun 26, 2026
traded Jun 26, 2026
+0dSEC FORM 4

Evidence

35
GM
Gloria MelanieChief Operating Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$116K
2,966 sh
Jun 26, 2026Jun 26, 2026
traded Jun 26, 2026
+0dSEC FORM 4

Evidence

42
SS
Stout Jay SChief Technology Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$1.27M
33.3K sh
Jun 26, 2026Jun 26, 2026
traded Jun 26, 2026
+0dSEC FORM 4

Evidence

35
SS
Stout Jay SChief Technology Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$262K
6,723 sh
Jun 26, 2026Jun 26, 2026
traded Jun 26, 2026
+0dSEC FORM 4

Evidence

15
VC
Van Tuyl ChristopherChief Legal Officer
IMVTImmunovant, Inc.
Option exercise
M$271K
17.8K sh
Jun 26, 2026Jun 26, 2026
traded Jun 26, 2026
+0dSEC FORM 4

Evidence

35
VC
Van Tuyl ChristopherChief Legal Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$111K
2,842 sh
Jun 26, 2026Jun 26, 2026
traded Jun 26, 2026
+0dSEC FORM 4

Evidence

38
GT
Girao TiagoChief Financial Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$385K
10.0K sh
Jun 26, 2026Jun 26, 2026
traded Jun 26, 2026
+0dSEC FORM 4

Evidence

5
GT
Girao TiagoChief Financial Officer
IMVTImmunovant, Inc.
Option exercise
M—
10.0K sh
Jun 26, 2026Jun 26, 2026
traded Jun 26, 2026
+0dSEC FORM 4

Evidence

0
PA
Pande AtulDirector
IMVTImmunovant, Inc.
Option exercise · 10b5-1 plan
M$13K
1,500 sh
Jun 26, 2026Jun 26, 2026
traded Jun 26, 2026
+0dSEC FORM 4

Evidence

8
GT
Girao TiagoChief Financial Officer
IMVTImmunovant, Inc.
Option exercise
M$159K
10.0K sh
Jun 26, 2026Jun 26, 2026
traded Jun 26, 2026
+0dSEC FORM 4

Evidence

25
SS
Stout Jay SChief Technology Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$82K
2,754 sh
Apr 23, 2026Apr 24, 2026
traded Apr 23, 2026
+1dSEC FORM 4

Evidence

36
GT
Girao TiagoChief Financial Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$763K
25.8K sh
Apr 23, 2026Apr 24, 2026
traded Apr 23, 2026
+1dSEC FORM 4

Evidence

30
SS
Stout Jay SChief Technology Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$214K
8,614 sh
Apr 8, 2026Apr 10, 2026
traded Apr 8, 2026
+2dSEC FORM 4

Evidence

30
VC
Van Tuyl ChristopherChief Legal Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$128K
5,165 sh
Apr 8, 2026Apr 10, 2026
traded Apr 8, 2026
+2dSEC FORM 4

Evidence

30
GM
Gloria MelanieChief Operating Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$217K
8,722 sh
Apr 8, 2026Apr 10, 2026
traded Apr 8, 2026
+2dSEC FORM 4

Evidence

27
SS
Stout Jay SChief Technology Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$38K
1,518 sh
Apr 8, 2026Apr 10, 2026
traded Apr 8, 2026
+2dSEC FORM 4

Evidence

17
GT
Girao TiagoChief Financial Officer
IMVTImmunovant, Inc.
Grant or award
A—
65.0K sh
Apr 7, 2026Apr 9, 2026
traded Apr 7, 2026
+2dSEC FORM 4

Evidence

17
TF
Torti FrankDirector
IMVTImmunovant, Inc.
Grant or award
A—
174.2K sh
Apr 7, 2026Apr 9, 2026
traded Apr 7, 2026
+2dSEC FORM 4

Evidence

9
TF
Torti FrankDirector
IMVTImmunovant, Inc.
Grant or award
A—
88.3K sh
Apr 7, 2026Apr 9, 2026
traded Apr 7, 2026
+2dSEC FORM 4

Evidence

13
FJ
Fromkin Andrew J.Director
IMVTImmunovant, Inc.
Grant or award
A—
13.9K sh
Apr 7, 2026Apr 9, 2026
traded Apr 7, 2026
+2dSEC FORM 4

Evidence

13
HJ
Hughes Douglas J.Director
IMVTImmunovant, Inc.
Grant or award
A—
13.9K sh
Apr 7, 2026Apr 9, 2026
traded Apr 7, 2026
+2dSEC FORM 4

Evidence

9
HJ
Hughes Douglas J.Director
IMVTImmunovant, Inc.
Grant or award
A—
7,061 sh
Apr 7, 2026Apr 9, 2026
traded Apr 7, 2026
+2dSEC FORM 4

Evidence

13
PA
Pande AtulDirector
IMVTImmunovant, Inc.
Grant or award
A—
13.9K sh
Apr 7, 2026Apr 9, 2026
traded Apr 7, 2026
+2dSEC FORM 4

Evidence

9
PA
Pande AtulDirector
IMVTImmunovant, Inc.
Grant or award
A—
7,061 sh
Apr 7, 2026Apr 9, 2026
traded Apr 7, 2026
+2dSEC FORM 4

Evidence

21
BJ
Bauer JakeDirector
IMVTImmunovant, Inc.
Grant or award
A—
13.9K sh
Apr 7, 2026Apr 9, 2026
traded Apr 7, 2026
+2dSEC FORM 4

Evidence

9
BJ
Bauer JakeDirector
IMVTImmunovant, Inc.
Grant or award
A—
7,061 sh
Apr 7, 2026Apr 9, 2026
traded Apr 7, 2026
+2dSEC FORM 4

Evidence

21
SG
Susman Robert GrahamDirector
IMVTImmunovant, Inc.
Grant or award
A—
13.9K sh
Apr 7, 2026Apr 9, 2026
traded Apr 7, 2026
+2dSEC FORM 4

Evidence

9
SG
Susman Robert GrahamDirector
IMVTImmunovant, Inc.
Grant or award
A—
7,061 sh
Apr 7, 2026Apr 9, 2026
traded Apr 7, 2026
+2dSEC FORM 4

Evidence

13
GM
Gloria MelanieChief Operating Officer
IMVTImmunovant, Inc.
Grant or award
A—
83.7K sh
Apr 7, 2026Apr 9, 2026
traded Apr 7, 2026
+2dSEC FORM 4

Evidence

5
GM
Gloria MelanieChief Operating Officer
IMVTImmunovant, Inc.
Grant or award
A—
121.1K sh
Apr 7, 2026Apr 9, 2026
traded Apr 7, 2026
+2dSEC FORM 4

Evidence

13
SS
Stout Jay SChief Technology Officer
IMVTImmunovant, Inc.
Grant or award
A—
66.9K sh
Apr 7, 2026Apr 9, 2026
traded Apr 7, 2026
+2dSEC FORM 4

Evidence

5
SS
Stout Jay SChief Technology Officer
IMVTImmunovant, Inc.
Grant or award
A—
96.9K sh
Apr 7, 2026Apr 9, 2026
traded Apr 7, 2026
+2dSEC FORM 4

Evidence

13
VC
Van Tuyl ChristopherChief Legal Officer
IMVTImmunovant, Inc.
Grant or award
A—
41.3K sh
Apr 7, 2026Apr 9, 2026
traded Apr 7, 2026
+2dSEC FORM 4

Evidence

5
VC
Van Tuyl ChristopherChief Legal Officer
IMVTImmunovant, Inc.
Grant or award
A—
59.8K sh
Apr 7, 2026Apr 9, 2026
traded Apr 7, 2026
+2dSEC FORM 4

Evidence

21
VE
Venker EricDirector, Chief Executive Officer
IMVTImmunovant, Inc.
Grant or award
A—
232.3K sh
Apr 7, 2026Apr 9, 2026
traded Apr 7, 2026
+2dSEC FORM 4

Evidence

9
VE
Venker EricDirector, Chief Executive Officer
IMVTImmunovant, Inc.
Grant or award
A—
336.0K sh
Apr 7, 2026Apr 9, 2026
traded Apr 7, 2026
+2dSEC FORM 4

Evidence

9
GT
Girao TiagoChief Financial Officer
IMVTImmunovant, Inc.
Grant or award
A—
94.0K sh
Apr 7, 2026Apr 9, 2026
traded Apr 7, 2026
+2dSEC FORM 4

Evidence

9
FJ
Fromkin Andrew J.Director
IMVTImmunovant, Inc.
Grant or award
A—
7,061 sh
Apr 7, 2026Apr 9, 2026
traded Apr 7, 2026
+2dSEC FORM 4

Evidence

20
VC
Van Tuyl ChristopherChief Legal Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$72K
2,877 sh
Mar 18, 2026Mar 20, 2026
traded Mar 18, 2026
+2dSEC FORM 4

Evidence

20
SS
Stout Jay SChief Technology Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$51K
1,977 sh
Jan 21, 2026Jan 23, 2026
traded Jan 21, 2026
+2dSEC FORM 4

Evidence

21
SS
Stout Jay SChief Technology Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$1,481
55 sh
Jan 7, 2026Jan 9, 2026
traded Jan 7, 2026
+2dSEC FORM 4

Evidence

21
SS
Stout Jay SChief Technology Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$30K
1,148 sh
Jan 7, 2026Jan 9, 2026
traded Jan 7, 2026
+2dSEC FORM 4

Evidence

24
VC
Van Tuyl ChristopherChief Legal Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$63K
2,284 sh
Dec 18, 2025Dec 19, 2025
traded Dec 18, 2025
+1dSEC FORM 4

Evidence

28
VC
Van Tuyl ChristopherChief Legal Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$228K
8,529 sh
Dec 18, 2025Dec 19, 2025
traded Dec 18, 2025
+1dSEC FORM 4

Evidence

28
GM
Gloria MelanieChief Operating Officer
IMVTImmunovant, Inc.
Open-market sale
SELL$241K
10.3K sh
Nov 20, 2025Nov 21, 2025
traded Nov 20, 2025
+1dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Hughes Douglas J.Director · Apr 9, 2026
  • ← Insider ofevidence
    Bauer JakeDirector · Apr 9, 2026
  • ← Insider ofevidence
    Susman Robert GrahamDirector · Apr 9, 2026
  • ← Insider ofevidence
    Venker EricDirector, Chief Executive Officer · Apr 9, 2026
  • ← Insider ofevidence
    Pande AtulDirector · Apr 9, 2026
  • ← Insider ofevidence
    Stout Jay SChief Technology Officer · Jan 9, 2026
  • ← Insider ofevidence
    Van Tuyl ChristopherChief Legal Officer · Dec 19, 2025
  • ← Insider ofevidence
    Gloria MelanieChief Operating Officer · Nov 21, 2025